“ ARCALYST® (rilonacept) Q1 2024 net product revenue of $78.9 million, representing 85% year-over-year growth ““ ARCALYST 2024 expected net product revenue increased to $370 - $390 million ““...
HAMILTON, Bermuda, April 16, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, April 23, 2024 at...
“ Abiprubart Phase 2b trial in Sjogren's Disease planned to initiate in 2H 2024 ““ Abiprubart Phase 2 Cohort 4 rheumatoid arthritis data further validate biological activity ““ Abiprubart development...
“ ARCALYST® (rilonacept) Q4 2023 and full-year 2023 net product revenue of $71.2 million and $233.2 million, respectively “ “ ARCALYST 2024 net product revenue expected to be $360 - $380 million,...
“ ARCALYST® (rilonacept) 2023 net product revenue grew ~90% year-over-year to $233.1 million (unaudited) “ “ ARCALYST 2024 net product revenue expected to be $360 - $380 million “ “ Abiprubart...
HAMILTON, Bermuda, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will present at the 42nd Annual J.P. Morgan Healthcare Conference on Monday,...
Kiniksa Reports Third Quarter 2023 Financial Results
HAMILTON, Bermuda, Oct. 24, 2023 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, October 31, 2023 at...
Why Shares of Kiniksa Pharmaceuticals Jumped Tuesday
– ARCALYST® (rilonacept) Q2 2023 net product revenue of $54.5 million –– ARCALYST 2023 net product revenue guidance increased to $220 - $230 million, representing ~84% year-over-year growth at the...